The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China

被引:8
作者
Tao, Jun [1 ]
Liang, Jun [2 ]
Zhang, Hui [2 ]
Pei, Lijian [2 ]
Qian, Han-zhu [1 ,3 ]
Chambers, Matthew C. [4 ]
Jiang, Yan [2 ]
Xiao, Yao [2 ]
机构
[1] Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA
[2] Chinese Ctr Dis Control & Prevent China CDC, Natl AIDS Reference Lab NARL, Natl Ctr AIDS STD Control & Prevent NCAIDS, Beijing, Peoples R China
[3] Vanderbilt Univ, Dept Med, Nashville, TN USA
[4] Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37235 USA
来源
PLOS ONE | 2015年 / 10卷 / 10期
关键词
HEPATITIS-C VIRUS; PEGYLATED INTERFERON; VIROLOGICAL RESPONSE; RISK FACTOR; HIV; THERAPY; SEROCONVERSION; TRANSMISSION; COMBINATION; PREVALENCE;
D O I
10.1371/journal.pone.0140263
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations. Methods Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU's virus, and performed a phylogenetic analysis to differentiate HCV subtypes. Results Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs. Discussion HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected.
引用
收藏
页数:9
相关论文
共 30 条
  • [1] Epidemiology of hepatitis C virus infection
    Alter, Miriam J.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) : 2436 - 2441
  • [2] Chronic hepatitis C virus infection: genotyping and its clinical role
    Bowden, D. Scott
    Berzsenyi, Mark D.
    [J]. FUTURE MICROBIOLOGY, 2006, 1 (01) : 103 - 112
  • [3] Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
    Bruno, S
    Silini, E
    Crosignani, A
    Borzio, F
    Leandro, G
    Bono, F
    Asti, M
    Rossi, S
    Larghi, A
    Cerino, A
    Podda, M
    Mondelli, MU
    [J]. HEPATOLOGY, 1997, 25 (03) : 754 - 758
  • [4] Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis
    Derbala, M
    Amer, A
    Bener, A
    Lopez, AC
    Omar, M
    El Ghannam, M
    [J]. JOURNAL OF VIRAL HEPATITIS, 2005, 12 (04) : 380 - 385
  • [5] Optimal therapy of hepatitis C
    Di Bisceglie, AM
    Hoofnagle, JH
    [J]. HEPATOLOGY, 2002, 36 (05) : S121 - S127
  • [6] Estimating progression to cirrhosis in chronic hepatitis C virus infection
    Freeman, AJ
    Dore, GJ
    Law, MG
    Thorpe, M
    Von Overbeck, J
    Lloyd, AR
    Marinos, G
    Kaldor, JM
    [J]. HEPATOLOGY, 2001, 34 (04) : 809 - 816
  • [7] Social circumstances of initiation of injection drug use and early shooting gallery attendance: Implications for HIV intervention among adolescent and young adult injection drug users
    Fuller, CM
    Vlahov, D
    Latkin, CA
    Ompad, DC
    Celentano, DD
    Strathdee, SA
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) : 86 - 93
  • [8] Coinfection with HIV and hepatitis C virus among injection drug users in southern China
    Garten, RJ
    Zhang, JB
    Lai, SH
    Liu, W
    Chen, J
    Yu, XF
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 : S18 - S24
  • [9] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
    Hadziyannis, SJ
    Sette, H
    Morgan, TR
    Balan, V
    Diago, M
    Marcellin, P
    Ramadori, G
    Bodenheimer, H
    Bernstein, D
    Rizzetto, M
    Zeuzem, S
    Pockros, PJ
    Lin, A
    Ackrill, AM
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) : 346 - 355
  • [10] Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion
    Hagan, H
    Thiede, H
    Des Jarlais, DC
    [J]. EPIDEMIOLOGY, 2004, 15 (05) : 543 - 549